These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 25712826

  • 1. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M, Shiraga F, Yamashita A, Shiragami C, Ono A, Shirakata Y, Kimura S, Shiode Y, Kawata T, Hosogi M, Fujiwara A, Morizane Y.
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [Abstract] [Full Text] [Related]

  • 2. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T.
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [Abstract] [Full Text] [Related]

  • 3. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C, Sawa M, Sayanagi K, Nishida K.
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [Abstract] [Full Text] [Related]

  • 4. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
    Ijiri S, Sugiyama K.
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y, Iwahashi C, Gomi F.
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW.
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [Abstract] [Full Text] [Related]

  • 7. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM, Koh HJ, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [Abstract] [Full Text] [Related]

  • 10. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M, Yamane S, Taoka R, Arakawa A, Kadonosono K.
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K.
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [Abstract] [Full Text] [Related]

  • 14. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
    Azuma K, Obata R, Nomura Y, Tan X, Takahashi H, Yanagi Y.
    Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
    [Abstract] [Full Text] [Related]

  • 15. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
    Jeong S, Sagong M.
    Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
    [Abstract] [Full Text] [Related]

  • 16. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
    Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, Kim CG, Kim JW.
    Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
    [Abstract] [Full Text] [Related]

  • 17. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
    Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ.
    Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
    [Abstract] [Full Text] [Related]

  • 18. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

  • 19. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H, Ji B, Chung H, Kim HC.
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.